Polyuria clinical trials
The registry lists 14 studies for Polyuria across more than 10 countries. 2 are recruiting or about to start. 7 of them are mainly about Polyuria (how this is decided). Per ClinicalTrials.gov, last updated 2026-08-25.
Get an email when these change. Save the Polyuria studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
University Hospital, Ghent (3) · Seoul National University Hospital (2) · Ferring Pharmaceuticals (2) · McMaster University (1) · Hospital Privado de Comunidad de Mar del Plata (1) · University of Wuerzburg (1) · University of Colorado, Denver (1) · University Medical Center Groningen (1)
What is being tested here
Drugs under test in Polyuria studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Hydrochlorothiazide | 1 | 1 | 1 |
| Sildenafil | 0 | 0 | 1 |
| Calcitonin | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Who these studies take
Of the 1 Polyuria studies recruiting now, 0 (0%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 1 (100%) | 1 (100%) |
| 30 | 1 (100%) | 1 (100%) |
| 40 | 1 (100%) | 1 (100%) |
| 50 | 1 (100%) | 1 (100%) |
| 65 | 1 (100%) | 1 (100%) |
| 75 | 1 (100%) | 1 (100%) |
| 85 | 0 (0%) | 0 (0%) |
Across all 14 studies, recruiting or not: 43% stop at 75 or younger and 36% at 65; 14% take children; 0% are for women only and 14% for men only; 21% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 14 of 14. search them.
- HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of LifeRecruitingNCT05373264Phase 37 countries
- Polyuria Associated With Dexmedetomidine in Operating RoomNot yet recruitingNCT06535386
- Food and Salt Handling in DiuresisCompletedNCT04526340Not applicable1 country
- Dietary Intervention in ADPKD on TolvaptanCompletedNCT03858439Not applicable1 country
- A Cross-Functional, Population-Representative, Web-Based, Epidemiologic Study to Estimate the Prevalence and Burden of Nocturia Due to Nocturnal Polyuria in the USCompletedNCT041251861 country
- Watershift - Pilot StudyCompletedNCT04520477Not applicable1 country
- Influence of Food-intake on Desmopressin Oral Tablets and MELT-formulationCompletedNCT01036841Phase 41 country
- Trial of SK-1404 for Nocturia Due to Nocturnal Polyuria in Japanese SubjectsCompletedNCT03116191Phase 21 country
- Pharmacologic Treatment of Congenital Nephrogenic Diabetes InsipidusCompletedNCT00478335Not applicable2 countries
- Evaluation of a Novel Electronic Urine Output Monitor (eUOM)CompletedNCT021957131 country
- The Effect of Combined Systematized Behavioural Modification Education Program (SyBeMeP) With DDAVP in Patients With NocturiaCompletedNCT015769001 country
- Copeptin in Differentiation of Polyuria and PolydipsiaCompletedNCT010568871 country
- Efficacy and Safety of Desmopressin (Nocturin®) 0.1 mg Tablets in Treatment of Nocturia in Participants With Benign Prostate Syndrome (BPS)CompletedNCT009022651 country
- Necessity for Repetitive Education of Behavioral ModificationCompletedNCT012802791 country